Adding allergen-specific immunotherapy (AIT) to biologic agents that inhibit type-2 pathways may enhance the short-term efficacy and safety profile of allergy treatment—a benefit already demonstrated for omalizumab, an anti-IgE monoclonal antibody (11, 12). Here, IGHE is linked to allergic disease.